Tauriga Sciences, Inc. Anticipates That Green Hygienics' Bamboo-Based 100% Tree-Free Medical Products to be Available for Commercial Marketplace Before the End of the Current Quarter

LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga" or "the Company"), a diversified life sciences company focused on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare businesses, has today announced that the Company anticipates that final packaged bamboo-based medical products will be available for commercial sale prior to the quarter's end. Recalling that the Company entered into an exclusive 5 year license agreement with Green Hygienics, Inc., a wholly-owned subsidiary of Green Innovations Ltd. (OTCQB:GNIN), on May 29, 2013, that covers the entirety of the continent of North America. The Companies have been meeting with medical product distributors, hospitals, individual medical practices, and adult home owners, with the shared goal of generating meaningful revenues during the remainder of calendar year 2013 and beyond. The availability of these commercial products, in their final branded packaging, is an important accomplishment for the both companies. The initial responses from potential customers have been very encouraging and successfully engineering the manufacturing logistics is a final step towards generating sales. 

Tauriga CEO Seth M. Shaw stated, "The Company has been working hard to generate interest from potential customers and is confident that there is a significant revenue opportunity derived from the license agreement. We are pleased that management of Green Hygienics has been able to complete its third party manufacturing process and potentially provide us with commercial ready product later this quarter. It is of utmost importance to the Company that revenues can be generated and that there is an opportunity to grow the business over the subsequent years."  

Additionally, the Company fully anticipates its filing of its Form 10-K for the year ended March 31, 2013 by no later than Monday, July 15, 2013. This falls within the time frame allowable by the extension filed on July 02, 2013 (http://ih.advfn.com/p.php?pid=nmona&article=58254349).

About Tauriga Sciences, Inc.

Tauriga Sciences, Inc. (TAUG) is a life sciences company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.taurigasciences.com.

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.

This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: For further information regarding Tauriga Sciences, Inc.
         Mr. Seth M. Shaw
         Chairman & Chief Executive Officer
         Tauriga Sciences, Inc.
         www.taurigasciences.com
         New York: +1-917-796-9926
         Montreal: +1-514-840-3697
         Email: sshaw@tauriga.com